Drug intelligence / Profile preview

EGTX006

Development stage: Preclinical
Lead developer: Engitix Therapeutics

Overview

EGTX006 is an experimental therapeutic candidate under development by Engitix for the treatment of advanced fibrosis. Discovered using Engitix's proprietary human extracellular matrix (ECM) platform, the drug is designed to target disease-specific changes within the ECM to halt or reverse fibrogenesis. The program is currently in the discovery stage of development, with its specific molecular target and modality remaining undisclosed.

Beyond the preview

Go deeper on EGTX006.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EGTX006.

Explore the full profile